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Abstract
At present, there is no efficient curative therapy for cancer patients with advanced metastatic disease. Targeting of antiapoptotic mol-
ecules acting on the mitochondrial apoptosis pathway could potentially augment antimetastatic effect of cytotoxic drugs. Similarly to
Bcl-2 family members, β-galactoside–binding lectin galectin-3 protects cancer cells from apoptosis induced by cytotoxic drugs through
the mitochondrial pathway. In this study, we tested the hypothesis that inhibiting galectin-3 antiapoptotic function using a synthetic
low–molecular weight carbohydrate-based compound lactulosyl-L-leucine (Lac-L-Leu) will augment apoptosis induced in human cancer
cells by paclitaxel and increase its efficacy against established metastases. Treatment with synthetic glycoamine Lac-L-Leu alone re-
duced the number of established MDA-MB-435Lung2 pulmonary metastases 5.5-fold (P = .032) but did not significantly affect the
incidence of metastasis. Treatment with paclitaxel alone (10 mg/kg three times with 3-day intervals) had no significant effect on the in-
cidence or on the number of MDA-MB-435Lung2 metastases. Treatment with Lac-L-Leu/paclitaxel combination decreased both the
number (P = .02) and the incidence (P = .001) of pulmonary metastases, causing a five-fold increase in the number of metastasis-
free animals from 14% in the control group to 70% in the combination therapy group. The median number of lung metastases dropped
to 0 in the combination therapy group compared with 11 in the control (P = .02). Synergistic inhibition of clonogenic survival and
induction of apoptosis in metastatic cells by Lac-L-Leu/paclitaxel combination was functionally linked with an increase in mitochondrial
damage and was sufficient for the antimetastatic activity that caused a reversal and eradication of advanced metastatic disease in 56%
of experimental animals.
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Introduction
Developing new approaches toward augmenting the efficacy of chemo-
therapy on advanced metastatic malignant disease is an important goal
of modern cancer research. Most currently used cytotoxic drugs act by
inducing neoplastic cell apoptosis through a mitochondrial pathway,
which is regulated largely by the Bcl-2 family proteins (reviewed in
Pommier et al. [1]). Deregulation of the Bcl-2 family in cancer cells,
leading to an imbalance in a relative ratio of proapoptotic (Bax, Bak,
Noxa, PUMA) to antiapoptotic (Bcl-2, Bcl-XL) members, modifies mi-
tochondria permeabilization, determines a threshold for apoptosis in-
duction, and contributes to the chemoresistance of malignant cells (see
Pommier et al. [1] and Reed [2] for review). Thus, Bcl-2 and Bcl-2–
related proteins in tumor cells have been targeted using various strat-
egies aiming at inducing apoptosis or enhancing an apoptotic response
to chemotherapy [2–5].
In the past several years, a compelling body of experimental evidence
has emerged suggesting that, in addition to the Bcl-2 family proteins,
a member of the galectin family, galectin-3, is also an important regu-
lator of the mitochondrial apoptosis pathway [6,7]. This β-galactoside–
binding protein shares with Bcl-2 the NWGRmotif [6], which is critical
for the Bcl-2 antiapoptotic activity and conserved within a BH1 domain
of the Bcl-2 family [8]. Galectin-3 was shown specifically to protect
cancer cells from apoptosis induced by various stimuli including serum
withdrawal, nitric oxide, and several cytotoxic drugs [6,7]. On cisplatin-
or staurosporine-induced apoptosis, galectin-3 translocates to the peri-
nuclear membrane and protects neoplastic cells from mitochondrial
damage and cytochrome c release [7]. These observations suggest that
galectin-3 protects tumor cells from apoptosis induced by cytotoxic
drugs by functioning on major apoptosis execution pathways. Indeed,
recent results from the group of Dr. Raz unambiguously demonstrate
that galectin-3 expression regulates the apoptotic response of prostate
cancer cells to chemotherapy through the mitochondrial apoptosis path-
way [9]. Therefore, one can reasonably expect that blocking galectin-3
antiapoptotic function could augment the cytotoxic effect of chemo-
therapeutic agents on cancer cells.
Importantly, galectins could be targeted efficiently by readily available
and nontoxic low–molecular weight carbohydrate-based compounds
[10,11]. In this study, we investigated whether lactulosyl-L-leucine
(Lac-L-Leu), a synthetic low–molecular weight carbohydrate-based
galectin-3 inhibitor, would increase susceptibility to apoptosis of the
human metastatic cancer cell MDA-MB-435 induced by Taxol (pacli-
taxel), a member of the taxane cytotoxic drug family becoming increas-
ingly important in the therapy for various cancers. Here, we report that
synthetic glycoamine Lac-L-Leu synergizes with paclitaxel to inhibit
clonogenic survival and induce apoptosis in MDA-MB-435 cells to
the extent sufficient to reduce paclitaxel IC50 (a concentration of the
compound causing 50% inhibition) in vitro seven-fold (from 1.4 to
0.2 nM). In vivo, the Lac-L-Leu/paclitaxel combination therapy caused
eradication of the established metastatic disease in 56% animals and sig-
nificant (>60%) inhibition of the incidence of established spontaneous
metastasis in the nude mouse model. To our knowledge, this is the first
study in which the reversal of the established metastatic disease using
carbohydrate-based combination therapy has been documented.
Materials and Methods
Cell Lines and Culturing Conditions
The MDA-MB-435 cell line was originally isolated from a pleural
effusion of a woman with metastatic breast adenocarcinoma [12].
The MDA-MB-435Lung2 variant was selected in vivo for its high
potential to develop spontaneous pulmonary metastasis from mam-
mary fat pad (MFP) tumors [13]. However, the identity of MDA-
MB-435 cells as breast carcinoma has recently been challenged [14].
Nevertheless, MDA-MB-435 cells and their derivatives remain one of
the most reliable in vivo models of spontaneous human cancer metas-
tasis. Thus, to avoid further controversy, we will refer to this cell line in
our study as to human metastatic cancer cells. MDA-MB-435 and
MDA-MB-435Lung2 cells were maintained in culture using mini-
mum essential medium supplemented with 5% fetal bovine serum,
sodium pyruvate, nonessential amino acids, L-glutamine, and two-fold
vitamin solution or RPMI-1640 medium supplemented with 2 mM
L-glutamine, 100 μg/ml gentamicin, and 10% fetal bovine serum. The
cultures were maintained on plastic in 5% CO2/95% air at 37°C in a
humidified incubator. All cultures were free of mycoplasma and the fol-
lowing murine viruses: reovirus type 3, pneumonia virus, K virus, Theiler
encephalitis virus, Sendai virus, minute virus, mouse adenovirus, mouse
hepatitis virus, lymphocytic choriomeningitis virus, ectromelia virus,
and lactate dehydrogenase virus (all assayed by MA Bioproducts,
Walkersville, MD).
In Vitro Clonogenic Survival and Growth Assay
MDA-MB-435 human cancer cells grown as monolayer cultures
were harvested using a standard trypsinization procedure and were
pipetted to produce a single cell suspension. Live cell counts were
obtained by Trypan blue dye exclusion assay. Cells were plated at a
low density (200 viable cells per well) in quadruplicate in 24-well
culture plates without (control samples) or in the presence of the
compounds tested. Seven days later, the cells were fixed with 2%
formaldehyde in PBS and stained with hematoxylin, and colonies
of more than 20 cells were scored. On the basis of these experiments,
the in vitro ICmin (a minimal concentration of the compound causing
a statistically significant inhibitory effect) and IC50 were determined.
Apoptosis Induction Experiments
MDA-MB-435 human cancer cells were plated as described in
clonogenic survival experiments without (untreated control) or in
the presence of ICmin of paclitaxel and Lac-L-Leu applied as single
agents or in combination. Identification of apoptotic cells was per-
formed 24 hours after plating using the terminal deoxynucleotidyl
transferase–mediated dUTP-X nick end labeling (TUNEL) method.
The In Situ Cell Death Detection Kit, POD (Roche Diagnostics, In-
dianapolis, IN) that uses fluorescein-dUTP and an antifluorescein
antibody conjugated to a peroxidase reporter molecule as a detection
reagent was used. The results shown are representative of at least two
separate experiments.
Monitoring Changes in Mitochondrial Membrane Potential
MDA-MB-435 cells were plated as for the clonogenic survival and
growth assay and treated with low (ICmin) concentrations of paclitaxel,
Lac-L-Leu, and their combination. After 24 hours, a 5-μg/ml solution of
5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylbenzimidazolylcarbocyanine
iodide (JC-1) in completemediumwas added to the cultures for 10min-
utes. Next, the cultures were rinsed with fresh cell culture media, and
two-color ratiometric confocal microscopy was performed using a
confocal microscopy system based on the Olympus IX81 inverted
microscope equipped with JC-1 filter cube (Chroma Technology,
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Rockingham, VT) to monitor changes in mitochondrial membrane
potential. At least 50 cells were observed for each experimental setting
in each well.
Western Blot Analysis
For the analysis of cytochrome c release from mitochondria and
caspase-3 cleavage, MDA-MB-435 cells were plated in multiple
T75 flasks at the 5 × 106-cell per flask density. Next day, the cells
were treated with increasing paclitaxel concentrations (0, 2.5, and
5.0 nM) with or without 500 μM of Lac-L-Leu. After 48 hours,
the cells were harvested using a standard trypsinization procedure,
and cytosolic fractions were obtained using a MITOISO2 mitochon-
dria isolation kit (Sigma, St Louis, MO). Protein concentrations were
determined using protein assay reagent (Bio-Rad, Hercules, CA), and
30 μg of cytosolic proteins from each sample was resolved on a 4%
to 12% Nu Page Bis Tris gel (Invitrogen, Carlsbad, CA). Proteins
were transferred onto a nitrocellulose membrane (Invitrogen). After
blocking the membranes with 5% nonfat milk, the rabbit polyclonal
antibodies against cytochrome c (no. 4272; Cell Signaling) and against
caspase-3 (no. 9662; Cell Signaling, Danvers, MA), which recog-
nize both the full-length caspase-3 (35 kDa) and the cleaved caspase-3
fragments (17 kDa), were used to analyze cytochrome c release and
caspase-3 cleavage, respectively. Bound antibodies were visualized using
horseradish peroxidase–conjugated secondary goat antirabbit antibody
(no. 7074; Cell Signaling) and enhanced chemical luminescence sys-
tem (GE Healthcare, Piscataway, NJ). Equal loading and transfer was
controlled using Ponceau S staining and anti–β-actin loading control
(Abcam, Cambridge, MA).
In Vivo Studies Using MDA-MB-435Lung2 Metastasis Model
A nude mouse model of spontaneous human cancer lung metastasis
[12] after MFP implantation of MDA-MB-435Lung2 cells was used
for evaluating the antimetastatic activity of Lac-L-Leu and paclitaxel
administered alone or in combination. The care and use of the animals
were in accordance with the University of Texas MD Anderson Cancer
Center’s Institutional Animal Care and Use Committee–approved pro-
tocol. Four- to five-week-old athymic NCr nu/nu female mice were
purchased from the Animal Production Area, NCI-Frederick Can-
cer Research Facility (Frederick, MD). Mice were anesthetized with
Metofane (Pitman Moore, Inc, Washington, NJ), and a 5-mm incision
was made in the skin over the lateral thorax. The MFP was exposed,
and 2 × 106 cells in a volume of 0.1 ml of PBS were injected into a fat
pad. The incision was closed with wound clips. The growth of the
tumors was monitored by weekly examination, and growth rates were
determined as the increase in mean tumor diameter, calculated from
caliper measurements of two orthogonal diameters.
Sixty-four mice were untreated until the mean tumor diameter
reached 8 mm, at which time lung micrometastases are established
in more than 80% of animals. At this time, daily intraperitoneal treat-
ment began with either 0.2 ml of PBS (43 mice) or 0.2 ml of glyco-
amines in PBS (21 mice). The primary tumors were resected when the
mean tumor diameter was 10 mm, and the mice were treated for a
further 5 weeks. The second arm of the treatment with either pacli-
taxel (10 mg/kg; 32 mice) or cremophor vehicle (21 mice) by intra-
venous injection commenced on day 14 after tumor removal and was
repeated twice at 3-day intervals. Mice were killed at the end of the
treatment schedule, or when moribund, and examined for lung metas-
tases both macroscopically and microscopically. The lungs and tumors
were fixed in 10% buffered formalin, and paraffin-embedded sections
stained with hematoxylin and eosin (H&E) were examined.
Glycoamine solutions were prepared daily by suspension of pre-
weighed aliquots in sterile PBS to a final concentration of 10 μM/
0.1 ml. The solutions were filtered through a 0.2-μm syringe filter be-
fore use. Paclitaxel was dissolved in Cremophor EL/ethanol (1:1 vol/vol)
at the concentration of 6 mg/ml and then diluted with PBS to
a final concentration of 1.25 mg/ml. Control vehicle was the same
Cremophor EL/ethanol preparation diluted 1:4.8 with PBS. Paclitaxel
and Cremophor EL were purchased from Sigma Chemical, Co. The
drug solution was prepared on each day of injection.
Statistical Analysis, Data Calculation, and Presentation
The results of clonogenic survival and apoptosis induction experi-
ments are presented as mean ± 1 SD. A 2-tailed paired Student’s t test
was used to evaluate the statistical significance of the difference be-
tween means. Statistical analysis of the incidence of lung metastasis
was performed using Fisher exact test. The significance of differences
in the numbers of lung metastasis was evaluated using the Mann-
Whitney rank sum test.
Results and Discussion
Lac-L-Leu and Paclitaxel Cause a Synergistic Effect on
Metastatic Cancer Cell Clonogenic Survival
Previously, we demonstrated that synthetic glycoamines, including
Lac-L-Leu, inhibit clonogenic survival and growth of metastatic mel-
anoma [15], breast carcinoma [11,15,16], prostate carcinoma [16],
and hemangiosarcoma [17] cells by interfering with β-galactoside–
mediated cell-to-cell and cell-to-matrix interactions [10,15,17]. Thus,
in this study, we have used a clonogenic survival assay to investigate
whether Lac-L-Leu and paclitaxel would act synergistically on MDA-
MB-435 human metastatic cancer cells in vitro. First, we assessed an
in vitro effect of various Lac-L-Leu concentrations on clonogenic sur-
vival of MDA-MB-435 cells. As expected, Lac-L-Leu caused dose-
dependent inhibition of the MDA-MB-435 cell clonogenic survival
and growth (Figure 1A) with maximal effect (complete inhibition)
occurring at ∼0.63 mM. On the basis of these experiments, we also
determined the in vitro ICmin and IC50 of Lac-L-Leu. In our exper-
iments, the in vitro ICmin of Lac-L-Leu was ∼100 μM, which repro-
ducibly caused 13% to 20% inhibition of the MDA-MB-435 cell
clonogenic survival, and IC50 was ∼157 μM.
Next, we investigated the effect of various paclitaxel concentrations
(from 0 to 3.0 ng/ml) on MDA-MB-435 in vitro clonogenic survival
alone or in combination with ICmin (100 μM) of Lac-L-Leu (Fig-
ure 1B). When used as a single agent, paclitaxel inhibited MDA-
MB-435 cell clonogenic survival in a dose-dependent manner, causing
a complete inhibition at the concentration of ∼3.5 nM (Figure 1B,
solid line with open circles). From these experiments, the in vitro ICmin
of paclitaxel was determined at 0.4 nM and IC50 was determined at
1.4 nM. After that, we titrated the paclitaxel effect on MDA-MB-435
cell clonogenic survival on the background of ICmin (100 μM) of
Lac-L-Leu. When paclitaxel was used in combination with the ICmin
of Lac-L-Leu (Figure 1B, solid line with closed circles), the effect of
paclitaxel on clonogenic survival and growth of MDA-MB-435 cells
was even greater.
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To determine whether this enhanced inhibition of MDA-MB-435
clonogenic survival, noted after a combined application of paclitaxel
and Lac-L-Leu, resulted from a simple summation of their respective
effects as single agents, or whether Lac-L-Leu indeed synergized with
paclitaxel, we generated a projected “would-be-additive-effect” line
by extrapolating the effects of Lac-L-Leu ICmin onto the paclitaxel
dose-dependent effect (Figure 1B, dotted line). The graph represent-
ing an actual combined effect of paclitaxel and Lac-L-Leu, however,
was significantly shifted to the left compared with the would-be-
additive-effect graph (Figure 1B, solid line with closed circles), pro-
viding evidence that Lac-L-Leu synergizes with paclitaxel when two
agents act on breast carcinoma cells simultaneously. This synergism
was sufficient to cause a reduction of paclitaxel IC50 seven-fold (from
1.4 nM as a single agent to 0.2 nM in combination with Lac-L-Leu).
In a separate series of clonogenic survival experiments, we used Lac-
L-Leu and paclitaxel at the ICmin concentrations either as single agents
or as a combination. As shown in Figure 1C , paclitaxel (0.4 nM) and
Lac-L-Leu (100 μM), when applied alone, caused a 12% and 13%
inhibition of clonogenic growth, respectively. However, their com-
bined application at these same concentrations resulted in a 61% in-
hibition of clonogenic survival (Figure 1C).
Synergistic Effect of Lac-L-Leu/Paclitaxel Combination on
Metastatic Cancer Cells Occurs through the Induction of
Apoptosis Associated with a Decrease in a Mitochondrial
Membrane Potential
Our next question was whether the effect of Lac-L-Leu/paclitaxel
combination on metastatic cancer cells is associated with an induction
of apoptosis. We therefore used a TUNEL assay to investigate whether
a combination of Lac-L-Leu with paclitaxel would cause a synergis-
tic induction of apoptosis in MDA-MB-435 cells. At 24 hours after
plating, apoptosis levels in cultures treated with paclitaxel (0.4 nM)
or Lac-L-Leu (100 μM) applied alone were at 13.7% and 15.8%, re-
spectively, compared with 10.2% in the untreated control (Figure 2,
A–E). However, when compounds were applied in combination, they
caused an induction of apoptosis in 77.5% of MDA-MB-435 cells
(Figure 2, A and E).
Because our original hypothesis was that Lac-L-Leu would enhance
the cytotoxic effect of paclitaxel by inhibiting galectin-3 antiapoptotic
function on the mitochondrial apoptosis pathway, we next investigated
the effect of paclitaxel, Lac-L-Leu, and their combination on mitochon-
drial membrane potential (ΔΨm). Again, we plated MDA-MB-435
cells as for the clonogenic growth assay and treated them with low
Figure 1. Synergistic effect of Lac-L-Leu and paclitaxel on MDA-MB-435 cell clonogenic survival and growth in vitro. (A) Dose-dependent
inhibition of MDA-MB-435 cell clonogenic survival by Lac-L-Leu. (B) Dose-dependent effect of paclitaxel alone (solid line with open
circles) or in combination with ICmin of Lac-L-Leu (solid line with closed circles) on MDA-MB-435 cell clonogenic survival and growth
in vitro. A projected would-be-additive-effect graph (dotted line) was generated by extrapolating the effect of Lac-L-Leu ICmin (gray area)
onto the effect of paclitaxel as a single agent (solid line with open circles). Yellow area represents a difference between the actual
effect Lac-L-Leu/paclitaxel combination and a projected would-be-additive-effect graph. Note a significant shift to the left of the graph
representing the effect of paclitaxel in combination with ICmin of Lac-L-Leu (solid line with closed circles) compared with the would-
be-additive-effect and paclitaxel-only graphs. Red area represents a fraction of surviving cells in combination therapy experiments.
(C) Effect of ICmin of paclitaxel (0.4 nM) and Lac-L-Leu (100 μM) when used as single agents or in combination on MDA-MB-435 clono-
genic survival.
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Figure 2. Synergistic induction of apoptosis by Lac-L-Leu/paclitaxel combination is associated with mitochondrial damage. (A) Effect of
ICmin of paclitaxel, Lac-L-Leu, and their combination on the induction of apoptosis in MDA-MB-435 cells compared with the untreated
control. (B–E) Neither paclitaxel (C) nor Lac-L-Leu (D) alone caused significant induction of apoptosis compared with the untreated con-
trol (B) at their respective ICmin concentrations. However, when the same concentrations of paclitaxel and Lac-L-Leu were applied to-
gether, they caused a dramatic increase in apoptosis levels (E). In B to E, clones containing at least one cell exhibiting TUNEL positivity
(light or dark brown staining) are enclosed into red rectangles. (F–I) Neither paclitaxel (G) nor Lac-L-Leu (H) alone significantly compro-
mised mitochondrial membrane potential at their respective ICmin compared with the untreated control (F). However, a combination of
two drugs at the same concentrations caused a dramatic drop in mitochondrial membrane potential (I) as revealed by JC-1 staining.
Numerical indices show mean ± SD percent of cells exhibiting mitochondrial catastrophe manifested by a complete or an almost com-
plete absence of J-aggregates. (J) Western blot analysis of cytochrome c release and caspase-3 cleavage. Note that Lac-L-Leu alone did
not induce either cytochrome c release or caspase-3 cleavage compared with the untreated control, whereas the Lac-L-Leu/paclitaxel
combination caused a significant increase in cytochrome c release at 5.0 nM paclitaxel concentration and an elevated caspase-3 cleav-
age at 2.5 and 5.0 nM paclitaxel concentrations compared with paclitaxel alone.
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(ICmin) concentrations of paclitaxel, Lac-L-Leu, and their combination.
Next day, we added 5 μg/ml of cell-permeable mitochondrial probe
JC-1 to the cultures for 10 minutes and used two-color ratiometric
confocal microscopy to monitor changes in mitochondrial membrane
potential. At high mitochondrial membrane potential, JC-1 forms
“J-aggregates” exhibiting a broad excitation spectrum and an emission
maximum at ∼590 nm (red fluorescence). However, as ΔΨm drops,
JC-1 dissociates into a green fluorescent monomeric form, thus allow-
ing for monitoring mitochondrial changes during apoptosis.
The results of these experiments (Figure 2, F–I ) revealed that, at
their respective ICmin, neither paclitaxel (Figure 2G ) nor Lac-L-Leu
(Figure 2H ) compromised cancer cell mitochondrial membrane po-
tential significantly compared with the untreated control (Figure 2F ).
However, a combination of the two drugs caused a dramatic drop in
ΔΨm (Figure 2I ). These results were in complete agreement with the
data from the apoptosis induction experiments and confirmed that
apoptosis induced in MDA-MB-435 cells by Lac-L-Leu/paclitaxel
combination is associated with mitochondrial damage. Indeed, as re-
vealed by Western analysis (Figure 2J ), a combined Lac-L-Leu/paclitaxel
application caused an increased cytochrome c release from mitochondria
and an elevated caspase-3 cleavage in MDA-MB-435 cells, indicating
further that the synergistic effect of Lac-L-Leu/paclitaxel combination
converges on the mitochondrial apoptosis pathway.
The Effect of Lac-L-Leu/Paclitaxel Combination on
Phosphorylation and Expression of the Bcl-2 Family Proteins
Because the mitochondrial apoptosis pathway is regulated pre-
dominantly by the Bcl-2 family, we next investigated whether the
effects of Lac-L-Leu and paclitaxel on the mitochondrial apoptosis
pathway are associated with changes in phosphorylation and expres-
sion of major antiapoptotic and proapoptotic Bcl-2 family proteins.
In these experiments, we did not register any significant changes in
the levels of expression of major antiapoptotic (Bcl-2, Bcl-XL, MCL-1)
and proapoptotic multidomain (Bax) or BH3-only (Bad, Bid, PUMA)
Bcl-2 family members in response to a treatment with paclitaxel, Lac-
L-Leu, or their combination (Figure 3). Paclitaxel, however, did cause
a significant increase in the Bcl-2 phosphorylation on Ser70 (Figure 3,
A and B). This result is consistent with previous reports from several
groups showing that apoptosis induced by paclitaxel in different types
of cancer is associated with an increase in Bcl-2 phosphorylation,
which diminishes its ability to sequestrate proapoptotic Bcl-2 family
members [18,19]. Interestingly, Lac-L-Leu did not effect paclitaxel-
induced Bcl-2 phosphorylation (Figure 3, A and B). It did reduce,
however, the phosphorylation of the BH3-only protein Bad on Ser112
(Figure 3, C and D) in cells treated with paclitaxel. This observa-
tion is in a complete agreement with recent results from the group
of Dr. Raz identifying galectin-3–induced Bad phosphorylation on
Ser112 as an important mechanism of galectin-3 antiapoptotic func-
tion in cancer cells [9]. A BH3-only protein Bad promotes apoptosis by
displacing a multidomain Bax from binding to Bcl-2 and Bcl-XL. The
phosphorylation of Bad on Ser112 induces Bad association with 14-3-
3 protein, thus precluding its interaction with Bcl-2 and Bcl-XL. The
fact that galectin-3 inhibitor Lac-L-Leu causes a significant decrease in
Bad Ser112 phosphorylation suggests that this could be an important
mechanism, by which Lac-L-Leu inhibits galectin-3 antiapoptotic
function and augments cancer cell apoptosis induced by paclitaxel.
In Vivo Effect of Lac-L-Leu/Paclitaxel Combination on
Established Metastatic Disease
Because our in vitro experiments showed that Lac-L-Leu can signif-
icantly augment the paclitaxel effect on MDA-MB-435 cells, our next
question was whether it would translate into an enhanced therapeutic
Figure 3.Western blot analysis of the expression and phosphorylation of major antiapoptotic (A and B) and proapoptotic (C and D) Bcl-2
family members in cells treated with Lac-L-Leu, Taxol, or their combination. Treatment with taxol caused a significant increase in Bcl-2
phosphorylation on Ser70, which was not affected by Lac-L-Leu (A and B). However, Lac-L-Leu inhibited the phosphorylation of Bad on
Ser112 in cells treated with taxol (C and D), suggesting that this could be a major mechanism by which Lac-L-Leu potentiates apoptosis
induced by taxol. B and D: bars show means ± SE of two independent experiments.
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effect on established human cancer metastasis in vivo. Previously, we
demonstrated that Lac-L-Leu is an efficient inhibitor of MDA-MB-
435 spontaneous lung metastasis in vivo [11]. Thus, in this study, we
have used MDA-MB-435Lung2 cells, which were selected for the
enhanced ability to develop spontaneous lung metastasis from MFP
tumors compared with the parental cells [13]. Further, MDA-MB-
435Lung2 are twice more resistant in vivo to the effect of Lac-L-Leu
([13] and this study) and only moderately responsive to paclitaxel
[20]. In addition, when designing our experiments, we attempted to
model a real-life clinical situation as close as possible. Thus, after trans-
planting tumors into MFP, we left them untreated until the mean
tumor diameter reached 8 mm. Only at this time, when lung micro-
metastases are already established in more than 80% of animals, daily
intraperitoneal injections with either PBS or Lac-L-Leu were initiated.
Primary tumors were removed surgically when their mean diameter
reached 10 mm, and paclitaxel was added to the regimens on day 14
after surgery as described in the Materials and Methods section.
As shown in Table 1, daily treatment with synthetic glycoamine
Lac-L-Leu alone did cause a significant reduction in the number of
Table 1. Inhibition of Established MDA-MB-435Lung2 Human Cancer Metastasis in Nude Mice
by Lac-L-Leu/Paclitaxel Combination.





Control‡ 86% (19/21) 11 (0-71)
Paclitaxel 68% (15/22) .134 7 (0-200) .39
Lac-L-Leu 64% (7/11) .147 2 (0-25) .032§
Paclitaxel + Lac-L-Leu 30% (3/10) .001§ 0 (0-30) .02§
*Incidence of metastasis (%) and number of mice with metastases/number of mice in parentheses.
The P values are the results of Fisher exact test analyses comparing each treatment group with the
control group.
†The number of macroscopic lung metastases is shown as median and range in parentheses. The
P values are the results of Mann-Whitney rank sum analyses comparing each treatment group
with the control group.
‡Cremophor vehicle control. Animals were administered cremophor vehicle intravenously on the
same schedule as paclitaxel.
§Indicates statistically significant difference compared with the control.
Figure 4. Histopathologic analysis of MDA-MB-435Lung2 spontaneous pulmonary metastasis. (A–D) High-resolution scans of the H&E–
stained whole lung cross sections. (E–H) Low-magnification photomicrographs of H&E–stained lung sections. Metastatic lesions appear
blue and are indicated with black arrows in panels A to D; marked with T in panels E to H. (I–L) Ki-67 staining (numerical indices show
percent of Ki-67–positive cells as mean ± SD from three observation fields). In panel L, red arrows point to an increased nuclear material
leakage into a cytoplasm. (M–P) H&E staining. In P, enhanced morphologic features of apoptosis such as nuclear fragmentation could be
observed in the areas indicated with red rectangles). (Q–T) TUNEL analysis revealed significantly higher percentage of apoptotic (brown
staining) cells in Lac-L-Leu/paclitaxel combination therapy group (T) compared with other groups. Apoptotic indices shown in the bottom
left corner of each photomicrograph represent mean ± SD from three observation fields. Original magnifications: E–H, ×40; I–T, ×400.
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MDA-MB-435Lung2 spontaneous lung metastasis. The median num-
ber of pulmonary metastases was reduced 5.5-fold from 11 in control
mice to 2 (P = .032) in mice treated with Lac-L-Leu (Table 1). How-
ever, the incidence of metastasis in this group was not affected signif-
icantly compared with that in the control. Although a trend toward the
inhibition of the incidence of pulmonary metastasis in mice treated
with Lac-L-Leu alone was noted (36% of mice in Lac-L-Leu–treated
group were metastasis-free compared with only 14% in the control
group), this difference was not statistically significant (Table 1). Treat-
ment with paclitaxel alone (10 mg/kg three times with 3-day intervals)
did not have a significant effect on the incidence or on the number of
MDA-MB-435Lung2 metastases (Table 1).
In contrast, when paclitaxel was used in combination with Lac-L-
Leu, a significant reduction in both the incidence and the numbers
of spontaneous metastases was observed (Table 1). The median num-
ber of metastases was reduced from 11 in the control group to 0 (P =
.02) in mice treated with Lac-L-Leu/paclitaxel combination. The
incidence of metastasis in mice treated with Lac-L-Leu/paclitaxel
combination was reduced 2.9-fold (P = .0013). At postmortem
examination, 70% of mice treated with Lac-L-Leu/paclitaxel combi-
nation were metastasis-free compared with only 14% in the control
group (Table 1).
Additional histopathologic examination did not reveal any occult
metastases that had not been detected at the necropsy. Further, many
of the metastatic lesions in Lac-L-Leu/paclitaxel–treated animals ap-
peared smaller than those in other groups both macroscopically (Fig-
ure 4, A–D) and microscopically (Figure 4, E–H ). However, the
number of animals with metastases and the number of metastatic le-
sions available for observation in a combination therapy group were
too small to make a statistically meaningful comparison. On the basis
of Ki-67 staining (Figure 4, I–L), there was no difference between
the groups in the rate of cancer cell proliferation within pulmonary
lesions. However, as manifested by an increased nuclear material
leakage into the cytoplasm (Figure 4L, red arrows) and enhanced
morphologic features of apoptosis such as nuclear fragmentation that
could be observed with H&E staining (Figure 4P, red rectangles),
enhanced apoptotic responses of tumor cells to the therapy were evi-
dent in Lac-L-Leu/paclitaxel–treated mice even at this stage. Indeed,
TUNEL analysis (Figure 4, Q–T ) yielded significantly higher apop-
totic indices in the Lac-L-Leu/paclitaxel combination therapy group
(Figure 4T ) compared with those in other groups.
The results presented in this study demonstrate that the low–
molecular weight synthetic carbohydrate-based galectin-3 inhibitor
Lac-L-Leu can enhance dramatically the paclitaxel effect on MDA-
MB-435 metastatic cancer cells in vitro and in vivo. Recently, we
showed that Lac-L-Leu and modified citrus pectin (MCP), yet another
carbohydrate-based galectin-3 inhibitor developed by the group of
Dr. Raz [21–23], sensitize hemangiosarcoma cells to apoptosis induced
by doxorubicin [17]. Further, in a related study, Chauhan et al. [24]
demonstrated that inhibition of galectin-3 antiapoptotic function by
MCP (GCS-100) was sufficient to reverse multiple myeloma cell re-
sistance to bortezomib and enhance their response to apoptosis in-
duced by dexamethasone in vitro.
Originally, both Lac-L-Leu and MCP were developed as potential
antimetastatic drugs because of their ability to inhibit metastasis-
associated tumor cell adhesive interactions mediated by galectin-3
[11,16,21,23]. As new evidence accumulate, indicating that galectin-
3 directly regulates the sensitivity of cancer cells to various chemother-
apeutic agents such as cisplatin [7,9], staurosporine [7], etoposide [9],
bortezomib [24], dexamethasone [24], and doxorubicin [17], it seems
that these low–molecular weight carbohydrate-based galectin-3 in-
hibitors may also hold the potential of dramatically enhancing cancer
cell sensitivity to cytotoxic drugs by suppressing galectin-3 antiapop-
totic effect on the mitochondrial apoptosis pathway. Thus, adding
carbohydrate-based inhibitors of β-galactoside–mediated interactions
to the treatment regimens of galectin-3–expressing malignancies may
represent a new paradigm of carbohydrate-based combination therapy
for cancer metastasis.
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